What is OpGen Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. OpGen's interest expense for the
three
months ended in Sep. 2023 was $ -0.40 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was $-2.34 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. OpGen's Operating Income for the
three
months ended in Sep. 2023 was $ -3.57 Mil. OpGen's Interest Expense for the
three
months ended in Sep. 2023 was $ -0.40 Mil.
OpGen did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
OpGen Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OpGen (NAS:OPGN) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
OpGen's Interest Expense for the
three
months ended in Sep. 2023 was $-0.40 Mil. Its
Operating Income
for the
three
months ended in Sep. 2023 was $-3.57 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Sep. 2023 was $2.83 Mil.
OpGen's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as
| OpGen did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
OpGen (OPGN) Business Description
Traded in Other Exchanges
Address
9717 Key West Avenue, Suite 100, Rockville, MD, USA, 20850
OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.
Executives
| Yvonne Schlaeppi |
director |
600 EAST GREENWICH AVENUE, WEST WARWICK X1 02893 |
| Johannes Bacher |
officer: Chief Operating Officer |
9717 KEY WEST AVENUE, SUITE 101, ROCKVILLE MD 20850 |
| Albert Weber |
officer: Chief Finanical Officer |
MARIENBURGER STR. 7, BERLIN 2M 10405 |
| Oliver Schacht |
director, officer: Chief Executive Officer |
9717 KEY WEST AVENUE, SUITE 101, ROCKVILLE MD 20850 |
| Evan/ Fa Jones |
director, officer: Chief Executive Officer |
C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878 |
| William E. Rhodes |
director |
C/O OPGEN, INC., 9717 KEY WEST AVE., SUITE 100, ROCKVILLE MD 20850 |
| Curetis N.v. In Liquidation |
10 percent owner |
MAX-EYTH-STRASSE 42, HOLZGERLINGEN 2M 71088 |
| Mario Crovetto |
director |
C/O OPGEN, INC., 9717 KEY WEST AVE., SUITE 100, ROCKVILLE MD 20850 |
| Prabhavathi Fernandes |
director |
114 MILTON AVENUE, CHAPEL HILL NC 27514 |
| Vadim M. Sapiro |
officer: Chief Information Officer |
C/O OPGEN, INC,, 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878 |
| Timothy C Dec |
officer: Chief Financial Officer |
C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878 |
| R Don Elsey |
director |
2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850 |
| Jven Capital, Llc |
10 percent owner |
P.O. BOX 60207, POTOMAC MD 20859 |
| Tina Susan Nova |
director |
C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
| Harry J D'andrea |
director |
6480 DOBBIN ROAD, COLUMBIA MD 21045 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OPGN has been successfully added to your 